SupCare
Phase NA Withdrawn
AMBER
Phase 2 Withdrawn
BOUNCE
Phase 2 Withdrawn
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Phase 2 Withdrawn
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
Chemo-free BRCA-targeted Neoadjuvant Strategy
Phase 2 Withdrawn
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Phase 1/2 Withdrawn
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Phase NA Withdrawn
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Phase 2 Withdrawn
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Phase 1/2 Withdrawn
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Phase 2 Withdrawn
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
Phase 2 Withdrawn
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
Phase 2 Withdrawn
PAMICC
Phase 2 Withdrawn
SOLUTION
Phase 2 Withdrawn
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
Phase 1/2 Withdrawn
PROMPT
Phase 2 Withdrawn
ADHERE
Phase 3 Withdrawn
H11
Phase 3 Withdrawn
Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma
Phase 1 Withdrawn
ARN-509
Phase 3 Withdrawn
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Phase 3 Withdrawn
TELEFIRST
Phase 3 Withdrawn
PERIDENO
Phase 2 Withdrawn
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Phase 2 Withdrawn
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
Phase NA Withdrawn
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
Phase 2 Withdrawn
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase 2 Withdrawn
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
Phase NA Withdrawn
BOS3
Phase 2/3 Withdrawn
MEGAN
Phase 2 Withdrawn
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
Lenvatinib in Second Line Endometrial Carcinoma
Phase 2 Withdrawn
TAK-700 in Castration Resistant Prostate Cancer
Phase 2 Withdrawn
A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer
Phase 2 Withdrawn
Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
Phase 2 Withdrawn
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Phase 2 Withdrawn
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
Phase 3 Withdrawn
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Phase 2 Withdrawn
S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx
Phase 2 Withdrawn
Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer
Phase 2 Withdrawn
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Phase 2 Withdrawn
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
Phase 2 Withdrawn
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Withdrawn
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
Phase 3 Withdrawn
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase 1 Withdrawn